In the group of patients receiving second-generation ALKis, the risk of death was independent of sex, age, body weight, smoking status, ALK gene abnormality diagnostic method, primary tumor size and location, lymph node metastasis, CNS and bone metastasis, and treatment complications. Here, ALK is linked to metastatic malignant neoplasm in the lymph nodes.